Chemical structure of molecule Vimseltinib (DCC-3014)

selective CSF1R kinase inhibitor

oral, 30 mg BIW, phase III, cancer

from structure-based design

Molecular Cancer Therapeutics

Deciphera Pharmaceuticals

The Deciphera CSF1R kinase inhibitor, vimseltinib (DCC-3014), is a selective oral TKI that induces an inactive conformation of CSF1R by biomimetically nucleating an array of 17 H-bonds in the switch control…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.